ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

In Brief: FDA Advisors Ask Cetus To Refine IL-2 Application; NIH Reauthorization Introduced

August 3, 1990

Proteomics Promises Ways To Track Response To Therapy

April 25, 2003

In Brief: Construction Grant Transfer To USC Approved; Illinois Director Says NCI Pushed Consortia

January 20, 1978

NCI Promises Strong Monitoring Process Visco Calls For Independent Review; Rep. Dingell Plans Hearing April 13

April 1, 1994

Consensus Conference agrees That Nevi Can Be Precursors For Melanoma, Offers Management Suggestions

November 4, 1983